Worldwide, approximately 185 million people are infected with HCV, and the distribution of HCV genotypes and subtypes varies by region. Currently, despite increasing levels of treatment, only a small proportion of all patients with hepatitis C are treated or cured. Study data show that of all patients diagnosed with hepatitis C, 39%, 19% and 13% were considered eligible for treatment, started and completed treatment, respectively, with only 3% ultimately achieving sustained virologic response (SVR). Currently approved direct antiviral agent (DAA) regimens offer many advantages over the original pegylated interferon (PEG-IFN) + ribavirin (RBV) regimen: shorter duration of therapy, SVR of approximately 90%, oral agents, and no interferon or even RBV. substantial research evidence suggests that novel interferon-free combination therapy is highly effective in patients with genotype 1 HCV, and A summary of eight phase III clinical studies published in N Engl J Med in 2014, including primary, treated and cirrhotic patients tolerated treatment regimens well with 8 to 24 weeks of therapy and SVR rates as high as 96%. More DAA combinations are expected to enter the clinic by 2016-2017, with a 1-pill-per-day regimen, no RBV, coverage of the full genotype, and a very short course of 4 to 8 weeks, allowing for a 95% SVR rate for all patients and for all stages of disease. A cure for hepatitis C and hepatitis C cirrhosis will be progressively achieved.